FDA Approves Navi Medical's First-of-its-Kind Neonav® ECG for Neonatal and Pediatric Care

Navi Medical Technologies has received 510(k) clearance from the U.S. Food and Drug Administration for its Neonav® ECG Tip Location System. The approval marks a major milestone in improving vascular access care for critically ill newborns and children.

The Neonav® is the first ECG-based tip location system designed specifically for neonatal and paediatric patients. It uses real-time ECG signal analysis to support accurate placement of Central Venous Access Devices (CVADs), which are essential for delivering medications and nutrients. Accurate placement helps avoid complications from misplacement or catheter movement—issues that cost hospitals in the United States up to USD$1 billion each year.

Unlike other systems, Neonav® is cleared for use in all patients, from premature infants to adults. It is the only system that supports placement of 1 French-sized catheters, which are commonly used for very small newborns. It can also be used for catheter placements both above and below the heart.

Additionally, the device offers a unique feature for ongoing monitoring of catheter position after initial placement, helping to detect any migration of the tip over time—something that has been difficult to manage until now.

Navi’s success is seen as a reflection of Victoria’s strength in medical research and advanced manufacturing, with benefits for both healthcare and the economy.